“Notably, we are presenting the first survival data for neoadjuvant Libtayo therapy in cutaneous squamous cell carcinoma and the first results for Libtayo in combination with ubamatamab, our investigational MUC16xCD3 bispecific antibody, in recurrent ovarian cancer. “Our data presentations at ESMO underscore Regeneron’s ability to apply a deep understanding of cancer biology, genetics and the immune system to advance the development of meaningful combinations for cancer types that have high unmet need,” said Israel Lowy, Senior Vice President, Translational and Clinical Oncology at Regeneron. The presentations demonstrate the role of Libtayo ® (cemiplimab) as both a monotherapy and a backbone of novel investigational combinations for various solid tumors. (NASDAQ: REGN) today announced the latest clinical data in early- and late-stage cancers from its oncology pipeline will be presented at the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 to 24 in Madrid, Spain. 15, 2023 (GLOBE NEWSWIRE) - Regeneron Pharmaceuticals, Inc. ![]() ![]() Event-free survival of investigational use of Libtayo ® (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be featured in oral presentationįirst data for the investigational combination of Libtayo and ubamatamab (MUC16xCD3) in recurrent ovarian cancer also to be presentedĪdditional presentations on outcomes of Libtayo-based therapy in advanced non-small cell lung cancer, including PD-L1 expression and histology specific subgroups
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |